Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.31 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL229973 | 0.87 | PAOX (0.43) | PAOXKMT2AMEN1LMNANPSR1 | |
| SCHEMBL1556386 | 0.86 | PAOX (0.52) | PAOXKMT2AMEN1NPSR1CYP2C19 | |
| SCHEMBL147326 | 0.82 | KMT2A (0.37) | PAOXKMT2AMEN1LMNANPSR1 | |
| SCHEMBL7366067 | 0.79 | PAOX (0.39) | PAOXKMT2AMEN1LMNANPSR1 | |
| SCHEMBL11323396 | 0.79 | PAOX (0.48) | PAOXKMT2AMEN1LMNANPSR1 | |
| SCHEMBL10713651 | 0.77 | CYP2C9 (0.54) | PAOXKMT2AMEN1LMNANPSR1 | |
| SCHEMBL8343447 | 0.77 | CYP2C19 (0.46) | PAOXKMT2AMEN1LMNANPSR1 | |
| SCHEMBL14037056 | 0.77 | PAOX (0.38) | PAOXKMT2AMEN1LMNANPSR1 | |
| SCHEMBL7994712 | 0.77 | PAOX (0.57) | PAOXKMT2AMEN1LMNANPSR1 | |
| SCHEMBL7926235 | 0.76 | CYP2C19 (0.35) | KMT2AMEN1LMNANPSR1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7972682-B2 | Reactive silicic acid suspensions | WACKER CHEMIE AG (DE) | 2011-07-05 | — | — | US | disclosed |
| US-20080113162-A1 | Reactive Silicic Acid Suspensions | WACKER CHEMIE AG (DE) | 2008-05-15 | — | — | US | disclosed |
| US-6956037-B2 | Benzamide derivatives for the treatment of diseases mediated by cytokines | ASTRAZENECA AB (SE) | 2005-10-18 | — | — | US | disclosed |
| EP-1077931-B1 | BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | ASTRAZENECA AB (SE) | 2004-11-17 | — | — | EP | disclosed |
| US-6800413-B2 | LOADING/REACTING HYDROPHILIC PYROGENIC SILICA WITH SILYLATING AGENT (METHYLTRICHLOROSILANE), THEN PURIFYING WITH INERT GAS | WACKER-CHEMIE GMBH (DE) | 2004-10-05 | — | — | US | disclosed |
| US-20030138715-A1 | Low-silanol silica | WACKER-CHEMIE GMBH (DE) | 2003-07-24 | — | — | US | disclosed |
| US-6579872-B1 | Such as TNF, in particular of TNF alpha, and various interleukins, in particular IL-1; N-(5-(4-(3-hydroxypropoxy)benzamido)-2-methylphenyl)-3,4-dimethoxybenzamide | ASTRAZENECA AB (SE) | 2003-06-17 | — | — | US | disclosed |
| EP-1077931-A1 | BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | AstraZeneca AB (SE) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999059959-A1 | BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | ASTRAZENECA AB (SE) | 1999-11-25 | — | — | WO | disclosed |
| EP-0852606-A1 | ORGANOPOLYSILOXANE COMPOUNDS CROSS-LINKABLE BY CLEAVING OF ALCOHOLS TO FORM ELASTOMERS | Wacker-Chemie GmbH (DE) | 1998-07-15 | — | — | EP | disclosed |
| WO-1997012939-A1 | ORGANOPOLYSILOXANE COMPOUNDS CROSS-LINKABLE BY CLEAVING OF ALCOHOLS TO FORM ELASTOMERS | WACKER-CHEMIE GMBH (DE) | 1997-04-10 | — | — | WO | disclosed |